Activity

The increasing activity in HBP Surgery during the past years, has allowed us to develop different types of procedures apart from the conventional liver transplantion. Among them, the use of livers from non heart beating donors, as well as starting in 2000 the first adult living donor liver transplantation program in Spain. Our long term result confirm the success of this type of transplantation achieving similar survival to that obtained after conventional cadaveric liver transplantation. A 99% survival rate at one year and 78% and 70% survival rate at 5 and 10 years. Besides we have been developing complex liver surgery procedures, specifically in relation to metastatic colorectal cancer liver disease (MCLD)  and Hepatocellular Carcinoma (HCC). We perfomed around 250 liver resections and 80 liver transplantations each year.

Lines of care

LIVING DONOR LIVER TRANSPLANTATION (LDLT)

Besides to the normal activity, we perform around 8-10 LDLT's each year. The usual indication is associated to Hepatitis B or C virus related problems, either Cirrhosis or Hepatocellular Carcinoma. Our group has designed an specific protocol in which extended indications beyond Milan Criteria are included. Specific care is taking in relation to the donor. Our results in the donor have been recently published and taking as the benchmarks for Major Liver Surgery.

HEPATOCELLULAR CARCINOMA

Is one of the most frequent indications for liver Surgery, as long as the liver function remains stable. It includes surveillance of patients affected of hepatitis B or C virus, local or regional treatment in terms of Radiofrequency or Microwave ablation as well as transarterial chemoembolization. Surgery remains the gold standard treatment whenever is possible. Procedures contemplates the possibility of laparoscopic segmental liver resection.

METASTATIC COLORECTAL CANCER LIVER DISEASE

Due to the high incidence in western countries of Colorectal cancer, metastatic liver disease is also one of the most important indications for liver surgery. As a reference center, the multidisciplinary approach includes a close relationship with our oncologists and radiologists in order to increase the possibility of a successful resection and recovery. This includes neoadjuvant as well as adjuvant chemotherapy, and/or portal embolization in order to increase the remnant liver volume.


The medical team is 100% dedicated to HOSPITAL. As a result, our patients are always seen by the same team of physicians and surgeons throughout the entire procedure.

Specially trained hospital nurses have extensive experience in the care of surgical or transplant patients with a nurse-to-patient ratio that is never more than 1:2.

Schedule an Appointment

Material resources

  • HOSPITAL ROOMS

  • DAY HOSPITAL 

  • SPECIFICALLY ORIENTED
    INTENSIVE CARE UNIT

  • HIGHLY TRAINED INTERVENTIONAL
    RADIOLOGY

  • LAST GENERATION
    CUSA DISECTOR FOR LIVER SURGERY

  • INTEGRATED OPERATING
    THEATER, INCLUDING 3d LAPAROSCOPIC TOWER

  • EXPERTISE IN ULTRASOUND
    EXPLORATION AND
    THERAPEUTIC PROCEDURES
    RFA AND MWA

  • INDOCYANIN GREEN
    (FLUORESCENCE) IMAGING TECHNIQUES

  • LAST GENERATION
    3D ULTRASOUND SCAN

Process

 

For patients affected of HCC or MCCLD:

    · Specific Multidisciplinary Approach Evaluation. Hepatology, Interventional Radiology and Surgery

 

Donor Evaluation:

    · Overall health status including psychological evaluation

    · Specific Liver Evaluation. Vascular and Biliary Distribution.

    · Sequential donor evaluation, including a transparent and strict donation process

 

Specifically Designed and equipped Integrated Operating Theater (x2)

    · Performance of the transplant in parallel (independent OR's). 

        - Right/Left Hepatic Donation/Retrieval

        - Patient Explant Hepatectomy and Implant

 

Strict Postoperative Follow up at ICU and Ward

 

Postrtansplant Long term Follow up of the donor and the patient

   

Our results

Liver Transplantation

Stem Cells Transplant

105

Living Donor Liver Transplantation

Survival Rate - Patient Survival

percutaneous coronary

99%

First year

percutaneous coronary

75%

For 5 years

Survival Rate - Graft Survival

percutaneous coronary

90%

First year

percutaneous coronary

70%

For 5 years


HEPATOCELLULAR CARCINOMA

Stem Cells Transplant

+300

HCC resected in the last ten years

Survival Rate

percutaneous coronary

75’6%

Overall Survival at 5 years

percutaneous coronary

38’6%

Disease Free Survival at 5 years


METASTATIC COLO-RECTAL LIVER DISEASE

Stem Cells Transplant

+400

Major Hepatectomies (2005-2015)

Survival Rate

percutaneous coronary

56,1%

Overall Survival at 5 years

percutaneous coronary

29,6%

Disease Free Survival at 5 years


Blog

  • Nueva Unidad de Trastorno del Espectro Alcohólico Fetal, diagnóstico y seguimiento multidisciplinar

    La nueva Unidad de TEAF (UneSAF) de Pediatria barnaclínic+ ofrece diagnóstico y seguimiento para niños afectados con el Trastorno del Espectro Alcohólico Fetal. Formada por un equipo multidisciplinar de referentes nacionales e internacionales con más de 15 años de experiencia en la clínica, investigación y docencia del TEAF. Además, se trata de la única Unidad […]

    Read more

  • Las únicas unidades de España de alta complejidad para enfermedades del hígado

    El grupo Hospital Clínic de Barcelona tiene una larga tradición en Hepatología. No en vano fue el primer centro en España en tener un Servició específico, fundado hace 50 años. Fue también el primero del país en tener una UCI de Enfermedades Hepáticas y una Unidad de Hemodinámica Hepática. Ambas fueron renovadas este año y […]

    Read more

  • Unidad de tabaquismo, el tratamiento más eficaz para dejar de fumar

    Desde hace unas semanas, Neumología barnaclínic+ cuenta con una Unidad específica para “dejar de fumar“. Liderada por el Dr. Jacobo Sellerés, la Unidad de tabaquismo barnaclínic+ se dedica al diagnóstico y tratamiento de esta enfermedad y está especializada en el manejo del paciente fumador complejo y del paciente con Enfermedades Pulmonares Intersticiales Difusas (EPID). ¿Cómo dejar de fumar? […]

    Read more